Lonza gains experienced scientific adviser

Company: Lonza

Professor Jonathan Knowles has joined Lonza Group in Switzerland as a part-time scientific adviser.

Professor Jonathan Knowles has joined Lonza Group in Switzerland as a part-time scientific adviser. In this role Knowles will be mainly supporting the LIFT (Lonza Innovation for Future Technologies) initiative, which aims to deliver long-term technology breakthroughs and new business platforms across all Lonza divisions. Knowles is a former member of the Roche executive committee and head of group research.

You may also like

Manufacturing

Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target

BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
Manufacturing

Swiss Rockets collaborates with Lonza to advance Torqur’s oncology drug candidate bimiralisib into late-stage clinical development

Lonza to provide cGMP manufacturing and technical support to advance bimiralisib into late-stage clinical development
Manufacturing

Lonza completes transformation to pure-play CDMO with agreement to divest Capsules & Health Ingredients

Sale of CHI business to Lone Star funds marks final step in Lonza’s strategic shift to a focused CDMO model
Ingredients

De-risk early stage drug development with Lonza Advanced Synthesis

Located at stand 5.1B76, Lonza is set to shed light on the issues facing drug developers and how AI-assisted tools improve the process
Drug Delivery

Lonza and Ethris team up to develop mRNA vaccines for respiratory diseases

The two hope to produce a temperature-stable mRNA vaccine for influenza, which may promote mucosal immunity through its nasal delivery system
Drug Delivery

Lonza and Iconovo collaborate to develop intranasal biologic for obesity

The two will aim to create an effective and stable inhaled formulation that can be used to treat obesity without the need for frequent injections
Manufacturing

Lonza’s Synaffix and Sidewinder Therapeutics sign multi-target ADC licensing agreement

Collaboration supports development of first-in-class bispecific ADCs for solid tumour indications
Subscribe now